December 2, 2018 - Page 2 of 2

NASDAQ Companies - December 2, 2018

Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab

Overall Response Rate (ORR) of 46% in Patients Receiving the Combination TLR4 Biomarker Continued to Show Higher Response Rate for […]

NASDAQ Companies - December 2, 2018

Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel

Results show high rates of Relapse Free Survival and Overall Survival in pediatric patients with acute leukemias with median follow-up […]

NYSE Companies - December 2, 2018

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies

Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in […]

NASDAQ Companies - December 2, 2018

Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome

Data Presented During Late-Breaker Session at 72nd American Epilepsy Society Annual Meeting Additional New Analyses Underscore Psychosocial Burden on Family EMERYVILLE, […]

page 2 of 2

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search